 Home > Biochemistry News > Biotechnology News > The overall response rate is 66.3%, and the mid-term results of the key clinical trial of innovative ADC are positive.

The overall response rate is 66.3%, and the mid-term results of the key clinical trial of innovative ADC are positive.

 Last Update: 2021-09-07
 Source: Internet
 Author: User

Tags

dehydration lab results

cell activity

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 22, 2021, ADC Therapeutics announced that its new antibody-conjugated drug (ADC) camidanlumab tesirine (Cami), which targets CD25, is in a pivotal phase 2 clinical trial for the treatment of patients with relapsed/refractory Hodgkin’s lymphoma Positive results

ADC is a new type of drug consisting of a monoclonal antibody targeting a specific tumor-associated antigen and a payload coupled to the antibody, combining the targeted delivery of the monoclonal antibody with the tumor-killing potential of the payload

The ongoing multi-center, open-label, single-group phase 2 clinical trial enrolled 117 patients with relapsed/refractory Hodgkin’s lymphoma.

▲The pyrrole benzodiazepine (PBD) dimer cytotoxin has a unique mechanism of action (picture source: ADC Therapeutics official website)

The main results of the interim analysis include:

The patient’s ORR was 66.

Note: The original text has been deleted

Reference materials:

[1] ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.